Science to practice: Can theranostic fullerenes be used to treat brain tumors?

Jeff W.M. Bulte

doi:10.1148/radiol.11111636

Science to practice: Can theranostic fullerenes be used to treat brain tumors?

Jeff W.M. Bulte

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

6 Scopus citations

Abstract

In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd₃N@C₈₀) labeled with lutetium 177(¹⁷⁷Lu) and tetraazacyclododecane tetraacetic acid (DOTA)(¹⁷⁷Lu-DOTA-f- Gd₃N@C₈₀) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.

Original language	English (US)
Pages (from-to)	1-2
Number of pages	2
Journal	Radiology
Volume	261
Issue number	1
DOIs	https://doi.org/10.1148/radiol.11111636
State	Published - Oct 1 2011

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1148/radiol.11111636

Cite this

@article{b6b002e56ca24e938ecb82d5ec15e637,

title = "Science to practice: Can theranostic fullerenes be used to treat brain tumors?",

abstract = "In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd3N@C80) labeled with lutetium 177(177Lu) and tetraazacyclododecane tetraacetic acid (DOTA)(177Lu-DOTA-f- Gd3N@C80) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.",

author = "Bulte, {Jeff W.M.}",

year = "2011",

month = oct,

day = "1",

doi = "10.1148/radiol.11111636",

language = "English (US)",

volume = "261",

pages = "1--2",

journal = "Radiology",

issn = "0033-8419",

publisher = "Radiological Society of North America Inc.",

number = "1",

}

TY - JOUR

T1 - Science to practice

T2 - Can theranostic fullerenes be used to treat brain tumors?

AU - Bulte, Jeff W.M.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd3N@C80) labeled with lutetium 177(177Lu) and tetraazacyclododecane tetraacetic acid (DOTA)(177Lu-DOTA-f- Gd3N@C80) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.

AB - In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd3N@C80) labeled with lutetium 177(177Lu) and tetraazacyclododecane tetraacetic acid (DOTA)(177Lu-DOTA-f- Gd3N@C80) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.

UR - http://www.scopus.com/inward/record.url?scp=80053069951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053069951&partnerID=8YFLogxK

U2 - 10.1148/radiol.11111636

DO - 10.1148/radiol.11111636

M3 - Short survey

C2 - 21931135

AN - SCOPUS:80053069951

SN - 0033-8419

VL - 261

SP - 1

EP - 2

JO - Radiology

JF - Radiology

IS - 1

ER -

Science to practice: Can theranostic fullerenes be used to treat brain tumors?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this